# Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

> **NCT02951845** · PHASE1 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-54416076 (Oral Suspension)
- **DRUG:** JNJ-54416076 (Formulation 1: Direct Compression Tablets)
- **DRUG:** JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)

## Key facts

- **NCT ID:** NCT02951845
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11-22
- **Primary completion:** 2017-02-17
- **Final completion:** 2017-02-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** JNJ-54416076 program has been stopped for strategic business reasons.
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951845, "Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02951845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*